Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Primary Cardiovascular Prevention in High-Risk Patients: A Systematic Review. [PDF]
Khan S +5 more
europepmc +1 more source
Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis. [PDF]
Matin A +5 more
europepmc +1 more source
Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm. [PDF]
Golledge J, Lu HS, Shah S.
europepmc +1 more source
Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment. [PDF]
Hamasaki M, Sakane N, Kotani K.
europepmc +1 more source
Retraction Note: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection. [PDF]
Muzammil K +7 more
europepmc +1 more source
Anti-inflammatory effects of proprotein convertase subtilisin/kexin 9 inhibitor therapy in the early phase of acute myocardial infarction. [PDF]
Shimizu T +12 more
europepmc +1 more source
Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease. [PDF]
Hettenbach A +9 more
europepmc +1 more source
Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia. [PDF]
Jiang H +12 more
europepmc +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Improves the Vascular Function of Arteriovenous Fistula in Rats with Hyperglycemia. [PDF]
Wang YC +8 more
europepmc +1 more source

